Ca. Slapak et al., INCREASED EFFLUX OF VINCRISTINE, BUT NOT OF DAUNORUBICIN, ASSOCIATED WITH THE MURINE MULTIDRUG-RESISTANCE PROTEIN (MRP), Biochemical pharmacology, 52(10), 1996, pp. 1569-1576
The multidrug resistance protein (MRP) is a membrane protein that medi
ates altered transport of cytotoxic drugs. Although MRP overexpression
has been described in doxorubicin-selected human tumor cell lines, th
e murine PC-V10 and PC-V40 cell lines are members of the only reported
series of vincristine-selected cell lines that overexpress mrp. Weste
rn blotting, using an antiserum developed against human MRP, demonstra
ted high-level expression of murine MRP primarily in the plasma membra
nes in each of the vincristine-selected cell lines. Only PC-V160, sele
cted for high level resistance, demonstrated concomitant overexpressio
n of the P-glycoprotein. As compared with parental cells, each of the
drug selected cell lines demonstrated an energy-dependent, decreased n
et accumulation of vincristine without any changes in the initial rate
s of vincristine influx. However, there was an enhanced rate of vincri
stine loss, 2.3-fold from the PC-V40 cell line and 3.9-fold from the P
C-V160 cell line. Selective plasma membrane permeabilization with digi
tonin equalized vincristine accumulation among the parental, the PC-V4
0, and the PC-V160 cell lines. No intracellular pH differences were de
tected among the cell lines. Despite high-level MRP expression, daunor
ubicin accumulation and the rate of daunorubicin loss in the PC-V40 ce
lls were the same as that observed in parental PC4 cells. Fluorescence
microscopy demonstrated no difference in the pattern of subcellular d
aunorubicin accumulation between parental and PC-V40 cells. These stud
ies demonstrate that murine MRP, overexpressed and found predominantly
in the plasma membrane of vincristine-selected PC-V40 cells, is assoc
iated with an energy-dependent increased efflux of vincristine, but no
t with efflux or altered distribution of daunorubicin. Copyright (C) 1
996 Elsevier Science Inc.